Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Axel Bex

Showing results (221-230 of 332) with videos related to

Pageof 34
Sort By:
European Urology|June 29, 2016
European Association of Urology Guidelines for Clear Cell Renal Cancers That Are Resistant to Vascular Endothelial Growth Factor Receptor-Targeted TherapyThomas Powles, Michael Staehler, Börje Ljungberg, et al.
European Urology|August 1, 2025
Epidemiology of Renal Cancer: Incidence, Mortality, Survival, Genetic Predisposition, and Risk FactorsAlessandro Larcher, Riccardo Campi, Axel Bex, et al.
Clinical Genitourinary Cancer|March 15, 2023
Baseline and Dynamic Changes in Hemoglobin Levels Predict Treatment Response and Prognosis in Metastatic Renal Cell Carcinoma: A Multicenter Retrospective StudyYu-Hsuen Yang, Sonam Ansel, Aafke Meerveld-Eggink, et al.
Critical Reviews in Oncology/Hematology|September 26, 2024
Outcome after treatment with axitinib in children, young adults, and adults with renal cell carcinoma: a narrative reviewJulia Sprokkerieft, Justine N van der Beek, Filippo Spreafico, et al.
European Urology Oncology|February 9, 2025
Towards a Consensus on the Management of Metastatic Renal Cell Carcinoma: Insights from a European Delphi StudyLaurence Albiges, Marine Gross-Goupil, Philippe Barthélémy, et al.
European Urology Open Science|January 13, 2022
Primary Renal Tumour Response in Patients Treated with Nivolumab and Ipilimumab for Metastatic Renal Cell Carcinoma: Real-world Data AssessmentAafke Meerveld-Eggink, Niels Graafland, Sofie Wilgenhof, et al.
Urologic Oncology|September 3, 2015
Lymph node count at radical cystectomy does not influence long-term survival if surgeons adhere to a standardized templateElisabeth E Fransen van de Putte, Tom J N Hermans, Erik van Werkhoven, et al.
European Urology Open Science|November 1, 2024
PrimerX: A Bayesian Multistage Cohort Embedded Randomised Trial to Evaluate the Role of Deferred Local Therapy of the Primary Tumour in Combination with Immune Checkpoint Inhibitor-based First-line Therapy in Metastatic Renal Cell Carcinoma PatientsOrlane Figaroa, Patricia Zondervan, Rob Kessels, et al.
International Journal of Radiation Oncology, Biology, Physics|July 15, 2022
Local Treatment of the Primary Tumor for Patients With Metastatic Cancer (PRIME-TX): A Meta-AnalysisJeffrey M Ryckman, Toms V Thomas, Ming Wang, et al.
European Urology|December 21, 2013
A hybrid radioactive and fluorescent tracer for sentinel node biopsy in penile carcinoma as a potential replacement for blue dyeOscar R Brouwer, Nynke S van den Berg, Hanna M Mathéron, et al.
Pageof 34

Showing results (221-230 of 332) with videos related to

Sort By:
Pageof 34
European Urology|June 29, 2016
European Association of Urology Guidelines for Clear Cell Renal Cancers That Are Resistant to Vascular Endothelial Growth Factor Receptor-Targeted TherapyThomas Powles, Michael Staehler, Börje Ljungberg, et al.
European Urology|August 1, 2025
Epidemiology of Renal Cancer: Incidence, Mortality, Survival, Genetic Predisposition, and Risk FactorsAlessandro Larcher, Riccardo Campi, Axel Bex, et al.
Clinical Genitourinary Cancer|March 15, 2023
Baseline and Dynamic Changes in Hemoglobin Levels Predict Treatment Response and Prognosis in Metastatic Renal Cell Carcinoma: A Multicenter Retrospective StudyYu-Hsuen Yang, Sonam Ansel, Aafke Meerveld-Eggink, et al.
Critical Reviews in Oncology/Hematology|September 26, 2024
Outcome after treatment with axitinib in children, young adults, and adults with renal cell carcinoma: a narrative reviewJulia Sprokkerieft, Justine N van der Beek, Filippo Spreafico, et al.
European Urology Oncology|February 9, 2025
Towards a Consensus on the Management of Metastatic Renal Cell Carcinoma: Insights from a European Delphi StudyLaurence Albiges, Marine Gross-Goupil, Philippe Barthélémy, et al.
European Urology Open Science|January 13, 2022
Primary Renal Tumour Response in Patients Treated with Nivolumab and Ipilimumab for Metastatic Renal Cell Carcinoma: Real-world Data AssessmentAafke Meerveld-Eggink, Niels Graafland, Sofie Wilgenhof, et al.
Urologic Oncology|September 3, 2015
Lymph node count at radical cystectomy does not influence long-term survival if surgeons adhere to a standardized templateElisabeth E Fransen van de Putte, Tom J N Hermans, Erik van Werkhoven, et al.
European Urology Open Science|November 1, 2024
PrimerX: A Bayesian Multistage Cohort Embedded Randomised Trial to Evaluate the Role of Deferred Local Therapy of the Primary Tumour in Combination with Immune Checkpoint Inhibitor-based First-line Therapy in Metastatic Renal Cell Carcinoma PatientsOrlane Figaroa, Patricia Zondervan, Rob Kessels, et al.
International Journal of Radiation Oncology, Biology, Physics|July 15, 2022
Local Treatment of the Primary Tumor for Patients With Metastatic Cancer (PRIME-TX): A Meta-AnalysisJeffrey M Ryckman, Toms V Thomas, Ming Wang, et al.
European Urology|December 21, 2013
A hybrid radioactive and fluorescent tracer for sentinel node biopsy in penile carcinoma as a potential replacement for blue dyeOscar R Brouwer, Nynke S van den Berg, Hanna M Mathéron, et al.
Pageof 34